{"id":"atezolizumab-or-durvalumab","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"20-30%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Muscle or bone pain"},{"rate":"10-20%","effect":"Rash"}]},"_chembl":{"chemblId":"CHEMBL3301587","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking PD-L1, these drugs allow the immune system to recognize and attack cancer cells more effectively. This is an example of immunotherapy, which works by enhancing the body's natural defenses against cancer. Atezolizumab and durvalumab have been shown to improve outcomes in various types of cancer, including non-small cell lung cancer and urothelial carcinoma.","oneSentence":"Atezolizumab and durvalumab are monoclonal antibodies that block the PD-L1 protein, preventing cancer cells from evading the immune system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:02:49.362Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Locally advanced or metastatic urothelial carcinoma"},{"name":"Locally advanced or metastatic non-small cell lung cancer"},{"name":"Locally advanced or metastatic triple-negative breast cancer"}]},"trialDetails":[{"nctId":"NCT06287775","phase":"PHASE1, PHASE2","title":"Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-04-08","conditions":"Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":45},{"nctId":"NCT04387084","phase":"PHASE1","title":"Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2020-08-12","conditions":"Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin Neoplasm","enrollment":10},{"nctId":"NCT04637594","phase":"PHASE3","title":"Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2022-05-27","conditions":"Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma","enrollment":3},{"nctId":"NCT04902040","phase":"PHASE1, PHASE2","title":"Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-04-14","conditions":"Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm","enrollment":19},{"nctId":"NCT05845450","phase":"PHASE2","title":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2023-05-11","conditions":"Colorectal Cancer, Resectable Colorectal Carcinoma","enrollment":197},{"nctId":"NCT05361395","phase":"PHASE1","title":"First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2022-08-24","conditions":"Extensive Stage Small Cell Lung Cancer","enrollment":184},{"nctId":"NCT03942328","phase":"PHASE1, PHASE2","title":"Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2019-09-19","conditions":"Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8","enrollment":85},{"nctId":"NCT06939036","phase":"PHASE1, PHASE2","title":"Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )","status":"TERMINATED","sponsor":"Ariceum Therapeutics GmbH","startDate":"2025-07-01","conditions":"Small Cell Lung Cancer Extensive Stage, Merkel Cell Carcinoma","enrollment":2},{"nctId":"NCT06898957","phase":"PHASE1","title":"Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)","status":"RECRUITING","sponsor":"Amgen","startDate":"2025-05-16","conditions":"Small Cell Lung Cancer","enrollment":200},{"nctId":"NCT07339059","phase":"PHASE2","title":"SG and Immunotherapy as Maintenance Therapy for Extensive-stage Small-cell Lung Cancer","status":"RECRUITING","sponsor":"Bindu R Potugari","startDate":"2026-02-01","conditions":"Small Cell Lung Cancer ( SCLC ), Extensive Stage Small Cell Lung Cancer (ES-SCLC)","enrollment":35},{"nctId":"NCT07166406","phase":"PHASE3","title":"Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2025-10-07","conditions":"Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8","enrollment":252},{"nctId":"NCT03228667","phase":"PHASE2","title":"QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2018-12-11","conditions":"Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma","enrollment":40},{"nctId":"NCT05733598","phase":"PHASE2","title":"Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC","status":"RECRUITING","sponsor":"Replimune Inc.","startDate":"2024-08-01","conditions":"Hepatocellular Carcinoma, Biliary Tract Cancer","enrollment":60},{"nctId":"NCT07224971","phase":"PHASE2","title":"Impact of Circadian Rhythm on Immunotherapy","status":"RECRUITING","sponsor":"Liza Villaruz, MD","startDate":"2025-12-02","conditions":"Advanced/Metastatic NSCLC","enrollment":350},{"nctId":"NCT06117891","phase":"","title":"An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery","status":"RECRUITING","sponsor":"Bayer","startDate":"2023-11-27","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":300},{"nctId":"NCT04954599","phase":"PHASE1, PHASE2","title":"Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI","status":"RECRUITING","sponsor":"Maastricht University Medical Center","startDate":"2023-05-30","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":126},{"nctId":"NCT07172412","phase":"PHASE2","title":"Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-11","conditions":"Extensive Stage Lung Small Cell Cancer","enrollment":165},{"nctId":"NCT06463665","phase":"PHASE2","title":"Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer","status":"RECRUITING","sponsor":"Genelux Corporation","startDate":"2024-09-26","conditions":"Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer","enrollment":142},{"nctId":"NCT06840782","phase":"PHASE3","title":"First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2025-09-09","conditions":"Oligometastatic Non-small Cell Lung Cancer (NSCLC)","enrollment":124},{"nctId":"NCT04513925","phase":"PHASE3","title":"A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-08-24","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":829},{"nctId":"NCT06529081","phase":"NA","title":"Radiotherapy Strategies for Use in Combined Treatment of Small-cell Lung Cancer","status":"RECRUITING","sponsor":"Copernicus Memorial Hospital","startDate":"2024-04-01","conditions":"Small Cell Lung Carcinoma","enrollment":165},{"nctId":"NCT06109272","phase":"PHASE2, PHASE3","title":"A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-01-11","conditions":"Hepatocellular Carcinoma","enrollment":660},{"nctId":"NCT06841172","phase":"PHASE3","title":"Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2025-07-21","conditions":"OligoProgressive Metastatic Disease, Hepatocellular Carcinoma (HCC), Radiotherapy","enrollment":132},{"nctId":"NCT07035860","phase":"","title":"Efficacy and Safety of Chemoimmunotherapy and Carbon Ion Radiotherapy in Unresectable Locally Advanced Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Ji Yongling","startDate":"2025-06-16","conditions":"Carbon Ion Radiotheray","enrollment":34},{"nctId":"NCT06429696","phase":"PHASE2","title":"PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2024-07-14","conditions":"Small Cell Lung Cancer Extensive Stage","enrollment":40},{"nctId":"NCT03212469","phase":"PHASE1, PHASE2","title":"A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2017-06-20","conditions":"Head and Neck Squamous Cell Carcinoma, Lung Cancer, Oesophageal Cancer","enrollment":54},{"nctId":"NCT06717243","phase":"","title":"Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)","status":"RECRUITING","sponsor":"Oncology Center of Biochemical Education And Research","startDate":"2025-02-20","conditions":"Small Cell Lung Cancer, Large Cell Neuroendocrine (NE) Tumors, Treatment Failure","enrollment":111},{"nctId":"NCT06869239","phase":"","title":"Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-02-25","conditions":"Limited-stage Small Cell Lung Cancer (LS-SCLC)","enrollment":65},{"nctId":"NCT04322643","phase":"PHASE2","title":"Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma","status":"TERMINATED","sponsor":"Case Comprehensive Cancer Center","startDate":"2020-03-23","conditions":"Urothelial Carcinoma","enrollment":4},{"nctId":"NCT06719336","phase":"PHASE3","title":"Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001)","status":"NOT_YET_RECRUITING","sponsor":"Anhui Shi, MD","startDate":"2024-12-16","conditions":"Extensive-stage Small Cell Lung Cancer","enrollment":182},{"nctId":"NCT06702566","phase":"NA","title":"The Effect of Serum Ferritin in irAE","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-07-04","conditions":"Immune-related Adverse Event, Malignant Solid Tumors, Acute Leukemia","enrollment":1500},{"nctId":"NCT06692491","phase":"PHASE2","title":"Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS","status":"NOT_YET_RECRUITING","sponsor":"Peking University Shenzhen Hospital","startDate":"2025-01-01","conditions":"Rare Tumour","enrollment":200},{"nctId":"NCT04504669","phase":"PHASE1","title":"First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-08-18","conditions":"Clear Cell Renal Cell Cancer, Non-Small-Cell Lung Cancer, Triple Negative Breast Neoplasms","enrollment":60},{"nctId":"NCT05934214","phase":"","title":"EXploring Immune-related Adverse Events of Immune checkpoinT Inhibitors Using VigiBase, the WHO Pharmacovigilance Database","status":"COMPLETED","sponsor":"Groupe Hospitalier Pitie-Salpetriere","startDate":"2023-01-01","conditions":"Cancer, Immune-related Adverse Event, Immune Checkpoint Inhibitor-Related Myocarditis","enrollment":141630},{"nctId":"NCT02925234","phase":"PHASE2","title":"The Drug Rediscovery Protocol (DRUP Trial)","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2016-08","conditions":"Cancer, Tumors, Neoplasm","enrollment":1550},{"nctId":"NCT02733042","phase":"PHASE1, PHASE2","title":"A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Celgene","startDate":"2016-05-11","conditions":"Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell","enrollment":106},{"nctId":"NCT04294771","phase":"","title":"JOint Use of Database to Identify Risk Factors of CARDio-vascular Toxicity Induced by Immune Checkpoint Inhibitors","status":"UNKNOWN","sponsor":"Groupe Hospitalier Pitie-Salpetriere","startDate":"2019-01-01","conditions":"Myocarditis, Cardiomyopathies, Heart Diseases","enrollment":500000},{"nctId":"NCT06031597","phase":"PHASE3","title":"Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2023-09-15","conditions":"Non-small Cell Lung Cancer Stage III","enrollment":105},{"nctId":"NCT05834413","phase":"NA","title":"Clinical Study on the Prevention of Driver Gene Negative II-IIIa Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2023-05-01","conditions":"Lung Cancer","enrollment":367},{"nctId":"NCT02890368","phase":"PHASE1","title":"Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides","status":"TERMINATED","sponsor":"Pfizer","startDate":"2016-09","conditions":"Solid Tumors, Mycosis Fungoides, Melanoma","enrollment":56},{"nctId":"NCT04107168","phase":"","title":"Microbiome Immunotherapy Toxicity and Response Evaluation","status":"UNKNOWN","sponsor":"CCTU- Cancer Theme","startDate":"2020-07-08","conditions":"Melanoma, Renal Cancer, Lung Cancer","enrollment":1800},{"nctId":"NCT05332496","phase":"","title":"TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC","status":"UNKNOWN","sponsor":"Zhongda Hospital","startDate":"2022-12-28","conditions":"Hepatocellular Carcinoma","enrollment":220},{"nctId":"NCT05332821","phase":"","title":"TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC","status":"UNKNOWN","sponsor":"Zhongda Hospital","startDate":"2022-12-28","conditions":"Hepatocellular Carcinoma","enrollment":474},{"nctId":"NCT05325684","phase":"PHASE1, PHASE2","title":"PD-L1 Inhibitor Rechallenge After PD-1 Immunotherapy for Patients With Solid Tumor Beyond Lung Cancer","status":"UNKNOWN","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2022-04","conditions":"Efficacy, Safety","enrollment":30},{"nctId":"NCT03056599","phase":"PHASE1","title":"Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"Presage Biosciences","startDate":"2016-12-15","conditions":"Soft Tissue Sarcoma Adult","enrollment":23},{"nctId":"NCT02777710","phase":"PHASE1","title":"Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers","status":"COMPLETED","sponsor":"Centre Leon Berard","startDate":"2016-06","conditions":"Colorectal Cancer, Pancreatic Cancer, Metastatic Cancer","enrollment":48},{"nctId":"NCT04898751","phase":"","title":"Analysis of Reporting of Cutaneous Toxicities Associated With Immune Checkpoint Inhibitors","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2008-01-01","conditions":"Cutaneous Toxicity From ICI Therapy","enrollment":2214},{"nctId":"NCT02311361","phase":"PHASE1, PHASE2","title":"Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2015-03-25","conditions":"Pancreatic Neoplasms, Pancreatic Cancer, Cancer of Pancreas","enrollment":65},{"nctId":"NCT02811497","phase":"PHASE2","title":"Study of Azacitidine and Durvalumab in Advanced Solid Tumors","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2016-09","conditions":"Microsatellite Stable Colorectal Carcinoma, Platinum Resistant Epithelial Ovarian Cancer Type II, Estrogen Receptor Positive and HER2 Negative Breast Cancer","enrollment":28},{"nctId":"NCT03721679","phase":"PHASE1, PHASE2","title":"Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1","status":"TERMINATED","sponsor":"Oncovir, Inc.","startDate":"2018-09-25","conditions":"Solid Cancer","enrollment":7},{"nctId":"NCT02423863","phase":"PHASE2","title":"In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®","status":"COMPLETED","sponsor":"Oncovir, Inc.","startDate":"2015-03","conditions":"Melanoma, Head and Neck Cancer, Sarcoma","enrollment":26},{"nctId":"NCT03544723","phase":"PHASE2","title":"Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.","status":"UNKNOWN","sponsor":"MultiVir, Inc.","startDate":"2018-10-01","conditions":"Solid Tumor, Lymphoma","enrollment":40},{"nctId":"NCT04355806","phase":"","title":"Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors","status":"UNKNOWN","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2020-06-01","conditions":"Non Small Cell Lung Cancer, Influenza Vaccine","enrollment":160},{"nctId":"NCT03492242","phase":"","title":"Immune CHeckpoint Inhibitors Monitoring of Adverse Drug ReAction","status":"COMPLETED","sponsor":"Groupe Hospitalier Pitie-Salpetriere","startDate":"2018-02-01","conditions":"Arthritis, Cancer, Cardiac Disease","enrollment":1000},{"nctId":"NCT03387540","phase":"","title":"Evaluation of Reporting of Immune Checkpoint Inhibitor Associated Cardio-vascular Adverse Reactions","status":"COMPLETED","sponsor":"Groupe Hospitalier Pitie-Salpetriere","startDate":"2017-12-02","conditions":"Myocarditis, Cardiac Complication","enrollment":104},{"nctId":"NCT02871323","phase":"PHASE1","title":"Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2016-11","conditions":"Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis","enrollment":""},{"nctId":"NCT02403271","phase":"PHASE1, PHASE2","title":"A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2015-03","conditions":"Non-Small Cell Lung Cancer, Breast Cancer, Pancreatic Cancer","enrollment":124}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7005,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"atezolizumab or durvalumab","genericName":"atezolizumab or durvalumab","companyName":"Anhui Shi, MD","companyId":"anhui-shi-md","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Atezolizumab and durvalumab are monoclonal antibodies that block the PD-L1 protein, preventing cancer cells from evading the immune system. Used for Locally advanced or metastatic urothelial carcinoma, Locally advanced or metastatic non-small cell lung cancer, Locally advanced or metastatic triple-negative breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}